Genpharmasec has recently experienced a change in its evaluation, reflecting a reassessment of its market position. The company reported net sales of Rs 6.03 crore for Q2 FY24-25, alongside a decline in profit before tax. Its return on equity stands at 5.78%, indicating challenges in profitability.

Genpharmasec, a microcap trading company, has received a 'Hold' rating from MarketsMOJO due to its stable financial position with a low Debt to Equity ratio and Mildly Bullish technical trends. However, the majority of shareholders are Non-Institutional investors and the company has a low ROE and expensive P/BV ratio. It has also underperformed in the past year and should be monitored before making any investment decisions.

Genpharmasec, a microcap trading company, has received a 'Sell' rating from MarketsMOJO due to poor management efficiency, flat quarterly results, expensive valuation, consistent underperformance, and lack of clear price momentum. Investors should carefully consider these factors before making any investment decisions.

Genpharmasec, a microcap trading company, has reported its financial results for the quarter ending September 2024. The company's stock has been given a 'Hold' call by MarketsMOJO. While the operating cash flow and PAT have shown positive trends, net sales and PBT have decreased. Investors are advised to monitor future reports for improvements.

Genpharmasec, a microcap trading company, has received a 'Hold' rating from MarketsMOJO due to its low Debt to Equity ratio and Mildly Bullish stock range. However, the company has a majority of non-institutional shareholders and poor management efficiency with a low ROE. Its stock is also trading at a premium compared to historical valuations. While it has shown some positive indicators, investors are advised to hold and monitor its performance closely.

Genpharmasec, a microcap trading company, has received a 'Sell' rating from MarketsMOJO due to poor management efficiency, low net sales, and expensive valuation. The company's profits have also fallen and it has underperformed the market. With a low Debt to Equity ratio and non-institutional shareholders, caution is advised for potential investors.

Genpharmasec, a microcap trading company, has received a 'Hold' rating from MarketsMOJO due to its low Debt to Equity ratio and Mildly Bullish trend. However, the stock's volatility and low Return on Equity raise concerns. Non-institutional investors make up the majority of shareholders, indicating potential market susceptibility. Careful consideration is advised before investing.

Genpharmasec, a microcap trading company, has received a 'Sell' rating from MarketsMOJO on October 3rd, 2024. This is due to poor management efficiency, low net sales, expensive valuation, and a negative return on profits. The stock's technical trend is also uncertain, making it a risky investment for non-institutional shareholders.

Genpharmasec, a microcap trading company, has received a 'Hold' rating from MarketsMOJO due to its low Debt to Equity ratio and Mildly Bullish stock range. However, the company's poor management efficiency and expensive valuation make it a risky investment. Non-institutional investors hold majority shares, indicating a lack of confidence from experienced investors.

Genpharmasec, a microcap trading company, was downgraded to 'Sell' by MarketsMOJO on September 16, 2024 due to poor management efficiency and low return on equity. The company's net sales for the quarter ending in June 2024 were at their lowest, and its stock is currently overvalued with a high price to book value. Additionally, the company's profits have decreased and its stock's trend is currently sideways. With a low debt to equity ratio and majority of non-institutional investors, investors should carefully consider these factors before making any investment decisions.

Genpharmasec, a microcap trading company, has received a 'Hold' rating from MarketsMOJO due to its low Debt to Equity ratio and Mildly Bullish stock range. However, the company's majority shareholders are Non-Institutional and it has shown poor management efficiency with a low ROE. Despite a high valuation and past stock returns, profits have decreased. Investors may want to wait for improved financial performance before investing.

Genpharmasec, a microcap trading company, has received a 'Sell' rating from MarketsMOJO due to its poor management efficiency and low Return on Equity (ROE) of 5.78%. The company's financial results for the quarter ending June 2024 were also flat, with a high ROE of 0.9 and overvalued stock price. Despite a 54.53% return in the past year, profits have declined and other factors such as low debt to equity ratio and non-institutional shareholders should be considered before investing.

Genpharmasec, a microcap trading company, has received a 'Hold' rating from MarketsMOJO on August 21, 2024. The company's low Debt to Equity ratio and positive technical trends have contributed to this upgrade. However, concerns over management efficiency and flat results in June 2024 may impact its profitability. The stock has underperformed the market in the past year, but with a 'Hold' rating, it may be worth monitoring for future developments.

Genpharmasec, a microcap trading company, has announced its financial results for the quarter ending March 2024. The company's stock has been given a 'Sell' call by MarketsMOJO. While the performance for the quarter was flat, the company's operating cash flow and profit margins have shown improvement. However, net sales have decreased, indicating areas for improvement.

Genpharmasec, a microcap trading company, reported a flat performance with a score of -2 in the December 2023 quarter, a decrease from 0 in the previous quarter. The company's struggles are reflected in its consistently decreasing PBT less Other Income over the last five quarters, with a low of Rs -0.11 crore in the latest quarter. MarketsMOJO has given a 'Sell' call for the company's stock based on its current financial performance.

Genpharmasec, a microcap trading company, has seen a surge in its stock price, reaching a 52-week high on January 16, 2024. It has outperformed the sector by 4.84% in the past 12 days, with a 160.14% return. The stock is currently trading above all its moving averages and has shown a remarkable growth of 201.37% in the past year, highlighting its strong performance in the trading industry.

Genpharmasec, a microcap trading company, has seen a remarkable 148.01% increase in returns over the past 11 days, reaching a 52-week high of Rs.6.97 on January 15, 2024. Despite being rated as 'Sell' by MarketsMOJO, the stock has outperformed the sector by 4.65% and is trading higher than all its moving averages, indicating a strong upward trend. Its 1-year performance of 192.42% also surpasses the overall market performance, making Genpharmasec a company to watch in the trading industry.

Genpharmasec, a microcap trading company, has seen a surge in its stock price, reaching a 52-week high on January 12, 2024. Despite being rated as 'Sell' by MarketsMOJO, the stock has outperformed the sector by 3.79% and has been on a consecutive upward trend for the past 10 days, with a remarkable 136.24% increase in returns. Its performance has consistently been higher than the moving averages and has shown an impressive 1-year performance of 181.41%, highlighting its potential for growth in the trading industry. Investors are advised to conduct their own research before investing.

Genpharmasec, a microcap company in the trading industry, has reached a new milestone as its stock price hit a 52-week high on January 11, 2024. Despite being rated as 'Sell' by MarketsMOJO, the stock has outperformed the sector by 4.27% in the past 9 days, with a significant increase of 125.18% in returns. The stock is currently trading above its moving averages and has shown an impressive 1-year performance of 163.57%, catching the attention of investors.